Erimos Pharmaceuticals is a biopharmaceutical company based in Houston, TX, dedicated to the discovery and development of small molecule therapeutics for the treatment of cancer and viral diseases. With a focus on innovative technology, Erimos aims to improve the lives and health outcomes of patients by inhibiting the expression of specific proteins over-expressed in cancer and demonstrating promising anti-viral results.
As a privately-held company, Erimos has conducted multiple clinical trials with their lead product, Terameprocol, which has shown long-term tolerability, disease stability, and anti-tumor activities. With a portfolio of licensed patents and partnerships with leading institutions, Erimos is actively seeking collaborations to further develop and commercialize their clinical stage compound for various diseases, including solid tumors, hematological malignancies, pre-neoplastic conditions, and viral infections.
Generated from the website